Educational note: This article is intended for general educational purposes only. It is not medical advice and does not suggest that cannabinoids treat, manage, or cure Parkinson's disease or any of its symptoms. Anyone considering questions about cannabinoids, dopamine, or Parkinson's disease should speak with their neurologist or physician before making any health-related decision.
The endocannabinoid system (ECS) and the brain's dopamine circuitry are two of the most studied signaling networks in neuroscience, and they happen to occupy overlapping territory in the brain. Regions dense with dopamine neurons and dopamine terminals, including the striatum, the substantia nigra, and the ventral tegmental area, are also rich in cannabinoid receptors. This anatomical overlap has led researchers to ask a mechanistic question that remains under active investigation: how, if at all, does cannabinoid receptor signaling shape dopamine activity in the brain, and what have imaging and laboratory studies actually shown so far. This piece walks through the current understanding of that relationship as a matter of neuroscience, not as a claim about treating any condition.
Two Systems That Share a Neighborhood
Dopamine is a neurotransmitter central to movement initiation, motivation, reward processing, and reinforcement learning. Dopaminergic neurons cluster largely in the substantia nigra pars compacta and the ventral tegmental area, projecting into the striatum and other forebrain targets as part of what is broadly known as the basal ganglia circuitry. This circuitry is the same system implicated in the motor symptoms associated with Parkinson's disease, which is why dopamine has long been a central focus of Parkinson's research.
The endocannabinoid system is a separate but anatomically intertwined signaling network. It consists of cannabinoid receptors (primarily CB1 and CB2), endogenous ligands called endocannabinoids (chiefly anandamide and 2-arachidonoylglycerol, or 2-AG), and the enzymes that synthesize and break them down. CB1 receptors are among the most abundant G protein-coupled receptors in the mammalian brain, and they are present at particularly high density in the basal ganglia, including the striatum, globus pallidus, and substantia nigra [4][5]. Because these are also the regions where dopamine neurons live and project, researchers have spent decades trying to characterize exactly how these two systems interact at the level of individual synapses.
Where CB1 Receptors Actually Sit
A key and somewhat counterintuitive finding from anatomical studies is that CB1 receptors are not typically located directly on dopamine neurons themselves. Detailed electron microscopy work mapping the subcellular location of CB1 receptors throughout the rat basal ganglia found that CB1 receptors are concentrated on axon terminals and preterminal axon segments, and that the large majority of these terminals are GABAergic, with a smaller population being glutamatergic [4]. In other words, CB1 receptors are positioned on the inhibitory and excitatory inputs that synapse onto dopamine neurons, rather than on the dopamine-releasing neurons themselves.
This distinction matters for how scientists think about cannabinoid-dopamine interactions. Rather than acting as a direct switch on dopamine neurons, cannabinoid receptor activity appears to work indirectly, by adjusting the balance of GABA (inhibitory) and glutamate (excitatory) signals arriving at dopamine neurons in regions like the substantia nigra and ventral tegmental area [4][6]. Because dopamine neuron firing is itself governed by this balance of excitatory and inhibitory input, changes at these GABAergic and glutamatergic terminals can, in principle, translate into downstream changes in dopamine neuron activity, even though the cannabinoid receptors are not sitting on the dopamine neurons directly. Review literature on the basal ganglia has described this arrangement as a tightly integrated, bidirectional relationship between the two systems, in which dopamine signaling can also influence endocannabinoid production, and not only the reverse [5].
Endocannabinoids as Retrograde Messengers
One of the defining features of endocannabinoid signaling is that it typically works "backward" relative to how neurotransmission is usually described. In most synaptic signaling, a presynaptic neuron releases a chemical messenger that acts on receptors on the postsynaptic neuron. Endocannabinoids largely reverse this direction. They are synthesized on demand in the postsynaptic neuron, often in response to depolarization or strong synaptic activity, and then travel backward across the synapse to activate CB1 receptors on the presynaptic terminal. This is commonly referred to as retrograde signaling, and it allows a postsynaptic neuron to dial down how much neurotransmitter (GABA or glutamate) the presynaptic terminal releases onto it [4][5].
This mechanism has been documented in the substantia nigra and elsewhere in the basal ganglia in a form often called depolarization-induced suppression of inhibition, or DSI, in which strong depolarization of a neuron triggers endocannabinoid release that transiently suppresses GABA release from its presynaptic inputs. This effect is blocked by CB1 receptor antagonists, supporting a specific role for the endocannabinoid system in this form of short-term synaptic plasticity [5]. Because dopamine neurons themselves can be depolarized by their own firing activity, and because their GABAergic and glutamatergic inputs carry CB1 receptors, this retrograde signaling loop is one proposed route by which endocannabinoid tone could indirectly modulate dopamine neuron excitability and, by extension, dopamine release patterns in target regions like the striatum and nucleus accumbens [8].
More recent work using modern circuit-tracing and electrophysiological tools has continued to refine this picture. A 2017 study in the journal Neuron, for example, examined how endocannabinoid signaling acting on cortical glutamatergic terminals shapes local dopamine release dynamics within the nucleus accumbens, describing a form of local circuit control in which cannabinoid signaling on cortical inputs, rather than on dopamine terminals directly, orchestrates dopamine release patterns in that region [8]. Findings like this reinforce the broader theme that cannabinoid-dopamine interactions in the brain tend to be indirect and circuit-dependent rather than a simple, direct chemical link.
What Human Imaging Studies Have Found
Because animal studies cannot fully answer how these interactions play out in living human brains, researchers have turned to positron emission tomography (PET) imaging using radiotracers that bind to dopamine D2/D3 receptors, most commonly [11C]raclopride. Since raclopride competes with endogenous dopamine for the same receptors, a drop in raclopride binding after a drug challenge is generally interpreted as reflecting increased synaptic dopamine release.
An early study using this approach in healthy volunteers found that inhaled THC reduced [11C]raclopride binding in the ventral striatum and precommissural dorsal putamen, interpreted by the authors as evidence of THC-induced dopamine release in these regions [1]. A later analysis combining data across two separate PET studies similarly reported a significant reduction in raclopride binding in the limbic striatum following THC administration, again consistent with a modest dopamine-releasing effect that appeared selective to particular striatal subregions rather than uniform across the whole striatum [2].
However, not every study has replicated this pattern. A separate PET investigation using a comparable oral THC dose, calibrated to approximate a standard cannabis cigarette, found no significant change in raclopride binding despite THC producing clear psychosis-like symptoms in participants, leading the authors to conclude that typical recreational THC doses may not reliably trigger measurable dopamine release in the human striatum [3]. Taken together, human imaging research in this area has produced what investigators themselves describe as mixed results, with some studies detecting a modest, regionally specific dopamine response to THC and others finding no significant effect. This inconsistency likely reflects differences in dose, route of administration, imaging methodology, and individual variability among study participants, and it means the human evidence base, while real, is not yet settled.
CBD and the Dopamine Receptor Question
Separately from THC's effects on dopamine release, some laboratory research has examined whether cannabidiol (CBD) interacts directly with dopamine receptors themselves, independent of the endocannabinoid system. Using cloned human dopamine receptors, one binding study reported that CBD acts as a partial agonist at a high-affinity state of the D2 receptor (referred to as D2High) and appeared to interact preferentially with D3 receptors as well, at concentrations the authors argued were consistent with CBD's studied clinical dosing in other contexts [7]. This line of research has largely been explored in the context of psychiatric conditions such as psychosis, and the receptor-binding behavior described is distinct from, and should not be conflated with, any claim about symptom benefit in neurological movement disorders. It is best understood as one data point in a broader, unresolved picture of how different cannabinoid compounds may interact with dopaminergic signaling through pathways beyond the classical CB1/CB2 receptor system.
An Active, Evolving, and Sometimes Contradictory Field
Taken as a whole, the research summarized here supports a few general, well-hedged conclusions rather than a single definitive mechanism. Cannabinoid receptors are anatomically positioned to influence dopamine circuits indirectly, largely through their dense presence on the GABAergic and glutamatergic terminals that regulate dopamine neuron firing, rather than through direct receptors on dopamine neurons themselves. Endocannabinoids function as retrograde messengers capable of adjusting the excitatory and inhibitory balance around dopamine neurons on a short timescale. Human imaging studies have found some, but not consistent, evidence that THC can alter striatal dopamine signaling as measured by PET, and separate laboratory work has raised questions about whether CBD interacts with dopamine receptors directly.
Because basal ganglia dopamine circuitry is central to Parkinson's disease research, some scientists have proposed that alterations in endocannabinoid signaling reported in Parkinson's disease may be relevant to understanding disease biology, and this is an area of ongoing academic interest [5][6]. It is important to be clear that this remains a subject of scientific inquiry rather than an established clinical pathway, and none of the findings described above translate into a claim that cannabinoid compounds treat, manage, or alter the course of Parkinson's disease or its symptoms. The neurochemical relationship between cannabinoids and dopamine is a genuinely active and still-developing area of neuroscience, marked by findings that sometimes point in different directions depending on the model system, dose, and method used to study it.
This article is provided for educational purposes only and does not constitute medical advice. It does not recommend, endorse, or claim any diagnostic, therapeutic, or disease-modifying use of cannabinoids for Parkinson's disease or any other condition. Readers should consult a qualified neurologist or physician before making decisions related to their health or treatment.
References
Bossong MG, van Berckel BNM, Boellaard R, et al. Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology. 2009;34(3):759-766. https://doi.org/10.1038/npp.2008.138
Bossong MG, Mehta MA, van Berckel BNM, Howes OD, Kahn RS, Stokes PRA. Further human evidence for striatal dopamine release induced by administration of Δ9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology. 2015;232(15):2723-2729. https://pmc.ncbi.nlm.nih.gov/articles/PMC4816196/
Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage. 2009;48(1):186-190. https://pubmed.ncbi.nlm.nih.gov/19539765/
Mátyás F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience. 2006;137(1):337-361. https://pubmed.ncbi.nlm.nih.gov/16289348/
García C, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. British Journal of Pharmacology. 2016;173(13):2069-2079. https://pmc.ncbi.nlm.nih.gov/articles/PMC4908199/
Mancini M, Calculli A, Di Martino D, Pisani A. Interplay between endocannabinoids and dopamine in the basal ganglia: implications for pain in Parkinson's disease. Journal of Anesthesia, Analgesia and Critical Care. 2024;4:33. https://doi.org/10.1186/s44158-024-00169-z
Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry. 2016;6(10):e920. https://pmc.ncbi.nlm.nih.gov/articles/PMC5315552/
Mateo Y, Johnson KA, Covey DP, et al. Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens. Neuron. 2017;96(5):1112-1126. https://doi.org/10.1016/j.neuron.2017.11.012